Neuronetics Target of Unusually Large Options Trading (NASDAQ:STIM)

Neuronetics, Inc. (NASDAQ:STIM) was the target of unusually large options trading on Thursday. Stock investors acquired 5,519 call options on the company. This represents an increase of approximately 905% compared to the typical daily volume of 549 call options.

Wall Street Analyst Weigh In

STIM has been the topic of a number of recent research reports. Wall Street Zen raised Neuronetics from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Neuronetics in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Neuronetics has a consensus rating of “Hold” and a consensus price target of $7.00.

Neuronetics Trading Up 9.2%

STIM stock traded up $0.18 during midday trading on Thursday, hitting $2.17. The stock had a trading volume of 260,931 shares, compared to its average volume of 1,412,538. Neuronetics has a 1-year low of $1.25 and a 1-year high of $5.92. The company has a current ratio of 2.24, a quick ratio of 2.09 and a debt-to-equity ratio of 2.09. The business has a fifty day moving average price of $1.56 and a two-hundred day moving average price of $2.69. The firm has a market cap of $148.90 million, a P/E ratio of -2.66 and a beta of 0.66.

Neuronetics (NASDAQ:STIM) last issued its earnings results on Tuesday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The business had revenue of $37.30 million during the quarter, compared to the consensus estimate of $37.85 million. Neuronetics had a negative return on equity of 131.15% and a negative net margin of 33.88%. On average, sell-side analysts predict that Neuronetics will post -1.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neuronetics

A number of hedge funds have recently added to or reduced their stakes in the company. UBS Group AG boosted its holdings in Neuronetics by 580.7% during the 3rd quarter. UBS Group AG now owns 2,164,831 shares of the company’s stock worth $5,910,000 after acquiring an additional 1,846,801 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Neuronetics by 2,993.3% during the first quarter. Goldman Sachs Group Inc. now owns 630,393 shares of the company’s stock worth $2,320,000 after purchasing an additional 610,014 shares during the last quarter. Geode Capital Management LLC grew its position in Neuronetics by 172.3% in the 2nd quarter. Geode Capital Management LLC now owns 879,045 shares of the company’s stock worth $3,068,000 after purchasing an additional 556,268 shares in the last quarter. Wexford Capital LP increased its stake in Neuronetics by 83.1% in the 3rd quarter. Wexford Capital LP now owns 1,177,225 shares of the company’s stock valued at $3,214,000 after buying an additional 534,155 shares during the last quarter. Finally, HighTower Advisors LLC lifted its position in shares of Neuronetics by 260.7% during the 3rd quarter. HighTower Advisors LLC now owns 577,069 shares of the company’s stock worth $1,575,000 after buying an additional 417,087 shares in the last quarter. Institutional investors and hedge funds own 53.59% of the company’s stock.

About Neuronetics

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.